A Phase 2 interventional study of Placebo and Low-Dose REGN4461 in Generalized Lipodystrophy, sponsored by Regeneron Pharmaceuticals. Completed at 8 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objectives of the study are to estimate the effects of REGN4461 on glycemic parameters in the subset of patients with elevated baseline hemoglobin A1c levels (HbA1c ≥7%) and to estimate the effects of REGN4461 on fasting triglyceride levels in the subset of patients with elevated baseline fasting triglycerides (TG ≥250 mg/dL).
The secondary objectives are to estimate the effects of REGN4461 on a composite endpoint of changes in either HbA1c or fasting TG for all patients, estimate the effects of 3 dose levels of REGN4461 on glycemic parameters and fasting TG, to estimate the effects of REGN4461 on insulin sensitivity, to evaluate the safety and tolerability of REGN4461 and to evaluate the pharmacokinetics (PK) and immunogenicity of REGN4461.
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Presence of one or both of the following metabolic abnormalities at screening:
Key Exclusion Criteria:
NOTE: Other protocol defined inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo · Drug: Low-Dose REGN4461 · Drug: High-dose REGN4461
Drug: Placebo · Drug: Low-Dose REGN4461 · Drug: High-dose REGN4461
Intravenous (IV) infusion loading dose or subcutaneous (SC) injection weekly (QW).
IV infusion loading dose or SC injection QW.
Also known as: mibavademab
IV infusion loading dose or SC injection QW.
Also known as: mibavademab
Absolute Change From Baseline in Participants With Elevated Baseline Hemoglobin A1c (HbA1c ≥7%) at Week 8
Absolute change from baseline in HbA1c for subgroup of participants with baseline HbA1c ≥7% reported
Time frame: Baseline, Week 8
Absolute Change From Baseline in Fasting Glucose at Week 8
Absolute change from baseline in fasting glucose for subgroup of participants with baseline HbA1c ≥7% reported
Time frame: Baseline, Week 8
Absolute Change From Baseline in Weighted Mean Glucose (WMG) at Week 8
Absolute change from baseline in WMG for subgroup of participants with baseline HbA1c ≥7% reported
Time frame: Baseline, Week 8
Percent Change From Baseline in Fasting Triglycerides (TG) at Week 8
Percent change from baseline in participants with elevated baseline fasting TG (fasting TG ≥250 mg/dL) reported
Time frame: Baseline, Week 8
Absolute Change From Baseline in HbA1c and Fasting TG Composite Endpoint at Week 8
The composite score is calculated for each individual participant using baseline and Week 8 measurements of HbA1c and fasting TG. For each participant, a Z-score is calculated separately for HbA1c and fasting TG, rescaling the change from baseline based on the standard deviation of the baseline value for all participants, as a way of standardizing the change value. The composite score uses one or both of the calculated Z-scores depending on which parameters were abnormal at baseline. If both, then the participant's composite is the average of the two parameter Z-scores. At the participant level, a Z-score of zero for either parameter indicates no change in that metabolic parameter, but a composite Z-score of zero can also reflect offsetting changes in metabolic parameters. A negative Z-score would be interpreted as an overall improvement in metabolic function, but a negative Z-score can also result from a decrease in one parameter not being canceled by an increase in the other.
Time frame: Baseline, Week 8
Absolute Change From Baseline in Fasting Glucose
Time frame: Baseline, Weeks 16, 24, 36, 52; OLTP 5 Weeks 4, 12, 24, 52
Absolute Change From Baseline in Fasting Glucose for Participants With Baseline HbA1c ≥7%
Time frame: Baseline, Weeks 16, 24, 36, 52; OLTP 5 Weeks 4, 12, 24, 52
Percent Change From Baseline in Fasting TG
Time frame: Baseline, Weeks 16, 24, 36, 52; OLTP 5 Weeks 4, 12, 24, 52
Percent Change From Baseline in Fasting TG for Participants With Baseline Fasting TG ≥250 mg/dL
Time frame: Baseline, Weeks 16, 24, 36, 52; OLTP 5 Weeks 4, 12, 24, 52
Absolute Change From Baseline in HbA1c
Time frame: Baseline, Weeks 16, 24, 36, 52; OLTP 5 Weeks 12, 24, 52
Absolute Change From Baseline in HbA1c for Participants With Baseline HbA1c ≥7%
Time frame: Baseline, Weeks 16, 24, 36, 52; OLTP 5 Weeks 12, 24, 52
Absolute Change From Baseline in Weighted Mean Glucose (WMG)
Time frame: Baseline, Weeks 16 and 24
Absolute Change From Baseline in WMG for Participants With Baseline Fasting HbA1c ≥7%
Time frame: Baseline, Weeks 16 and 24
Change From Baseline in Glucose Area Under the Concentration-time Curve (AUC0-4) During a Mixed Meal Tolerance Test (MMTT)
Time frame: Baseline, Weeks 8, 16, 24
Change From Baseline in Glucose AUC0-4 During a MMTT for Participants With Baseline HbA1c ≥7%
Time frame: Baseline, Weeks 8, 16, 24
Change From Baseline in Glucose Infusion Rate Per Kilogram (kg) Body Mass During Hyperinsulinemia-euglycemic Clamp
Time frame: Baseline, Weeks 8 and 52
Change From Baseline in Glucose Infusion Rate Per kg Body Mass During Hyperinsulinemia-euglycemic Clamp for Participants With Baseline HbA1c ≥7%
Time frame: Baseline, Weeks 8 and 52
Change From Baseline in Glucose Clearance Rate (kITT) During Insulin-tolerance Test (ITT)
Time frame: Baseline, Weeks 8 and 52
Change From Baseline in Glucose kITT During ITT for Participants With Baseline HbA1c ≥7%
Time frame: Baseline, Weeks 8 and 52
Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE)
Time frame: From first dose of DBTP study treatment through last dose of OLTP 5 study treatment plus 16 weeks (approximately 120 weeks)
Concentrations of Total REGN4461 in Serum Over Time
Time frame: Weeks 0 (post-dose), 8, 16 (post-dose), 36, 52; OLTP 5 Weeks 4, 12, 24, 52
Number of Participants With Anti-drug Antibodies (ADA) to REGN4461
Time frame: Approximately Week 128
| Milestone | Treatment Sequence A, DBTP 1: Placebo SC QW | Treatment Sequence B, DBTP 1: Low-dose REGN4461 SC QW | Treatment Sequence A, DBTP 2: Low-dose REGN4461 SC QW | Treatment Sequence B, DBTP 2: Medium-dose REGN4461 SC QW | Treatment Sequence A, DBTP 3: Medium-dose REGN4461 SC QW | Treatment Sequence B, DBTP 3: Medium-dose REGN4461 SC QW | Treatment Sequence A, OLTP 4: Medium-dose REGN4461 SC QW | Treatment Sequence B, OLTP 4: Medium-dose REGN4461 SC QW | Treatment Sequence A, OLTP 5: High-dose | Treatment Sequence B, OLTP 5: High-dose |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 8 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 8 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence A, DBTP 1: Placebo SC QW | Treatment Sequence B, DBTP 1: Low-dose REGN4461 SC QW | Treatment Sequence A, DBTP 2: Low-dose REGN4461 SC QW | Treatment Sequence B, DBTP 2: Medium-dose REGN4461 SC QW | Treatment Sequence A, DBTP 3: Medium-dose REGN4461 SC QW | Treatment Sequence B, DBTP 3: Medium-dose REGN4461 SC QW | Treatment Sequence A, OLTP 4: Medium-dose REGN4461 SC QW | Treatment Sequence B, OLTP 4: Medium-dose REGN4461 SC QW | Treatment Sequence A, OLTP 5: High-dose | Treatment Sequence B, OLTP 5: High-dose |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 8 | 8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 8 | 8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence A, DBTP 1: Placebo SC QW | Treatment Sequence B, DBTP 1: Low-dose REGN4461 SC QW | Treatment Sequence A, DBTP 2: Low-dose REGN4461 SC QW | Treatment Sequence B, DBTP 2: Medium-dose REGN4461 SC QW | Treatment Sequence A, DBTP 3: Medium-dose REGN4461 SC QW | Treatment Sequence B, DBTP 3: Medium-dose REGN4461 SC QW | Treatment Sequence A, OLTP 4: Medium-dose REGN4461 SC QW | Treatment Sequence B, OLTP 4: Medium-dose REGN4461 SC QW | Treatment Sequence A, OLTP 5: High-dose | Treatment Sequence B, OLTP 5: High-dose |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 8 | 8 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 8 | 8 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence A, DBTP 1: Placebo SC QW | Treatment Sequence B, DBTP 1: Low-dose REGN4461 SC QW | Treatment Sequence A, DBTP 2: Low-dose REGN4461 SC QW | Treatment Sequence B, DBTP 2: Medium-dose REGN4461 SC QW | Treatment Sequence A, DBTP 3: Medium-dose REGN4461 SC QW | Treatment Sequence B, DBTP 3: Medium-dose REGN4461 SC QW | Treatment Sequence A, OLTP 4: Medium-dose REGN4461 SC QW | Treatment Sequence B, OLTP 4: Medium-dose REGN4461 SC QW | Treatment Sequence A, OLTP 5: High-dose | Treatment Sequence B, OLTP 5: High-dose |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 8 | 0 | 0 |
| Completed oltp 4 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 8 | 0 | 0 |
| Entered oltp 4 extension | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 4 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 0 | 0 |
| Withdrew: Completed wk 52; did not enter oltp 4 extension | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up during oltp 4 extension | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Completed wk 52; discontinued during oltp4 ext. pi/participant decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Treatment Sequence A, DBTP 1: Placebo SC QW | Treatment Sequence B, DBTP 1: Low-dose REGN4461 SC QW | Treatment Sequence A, DBTP 2: Low-dose REGN4461 SC QW | Treatment Sequence B, DBTP 2: Medium-dose REGN4461 SC QW | Treatment Sequence A, DBTP 3: Medium-dose REGN4461 SC QW | Treatment Sequence B, DBTP 3: Medium-dose REGN4461 SC QW | Treatment Sequence A, OLTP 4: Medium-dose REGN4461 SC QW | Treatment Sequence B, OLTP 4: Medium-dose REGN4461 SC QW | Treatment Sequence A, OLTP 5: High-dose | Treatment Sequence B, OLTP 5: High-dose |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 4 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
The composite score is calculated for each individual participant using baseline and Week 8 measurements of HbA1c and fasting TG. For each participant, a Z-score is calculated separately for HbA1c and fasting TG, rescaling the change from baseline based on the standard deviation of the baseline value for all participants, as a way of standardizing the change value. The composite score uses one or both of the calculated Z-scores depending on which parameters were abnormal at baseline. If both, then the participant's composite is the average of the two parameter Z-scores. At the participant level, a Z-score of zero for either parameter indicates no change in that metabolic parameter, but a composite Z-score of zero can also reflect offsetting changes in metabolic parameters. A negative Z-score would be interpreted as an overall improvement in metabolic function, but a negative Z-score can also result from a decrease in one parameter not being canceled by an increase in the other.
| Z-score | Treatment Sequence A: DBTP 1: | Treatment Sequence B: DBTP 1 |
|---|---|---|
| Absolute Change From Baseline in HbA1c and Fasting TG Composite Endpoint at Week 8 | 0.0 ± 0.2 | 0.1 ± 0.3 |
| mg/dL | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| Week 16 | -29.4 ± 59.80 | -22.0 ± 47.85 |
| Week 24 | -68.8 ± 58.74 | -21.1 ± 82.85 |
| Week 36 | -47.6 ± 71.04 | 12.5 ± 119.63 |
| Week 52 | -55.1 ± 77.97 | 6.9 ± 68.64 |
| OLTP 5 Week 4 | -91.8 ± 61.29 | -39.8 ± 45.36 |
| OLTP 5 Week 12 | -82.9 ± 63.16 | -119.9 ± 64.64 |
| OLTP 5 Week 24 | -100.5 ± 55.15 | -40.7 ± 110.20 |
| OLTP 5 Week 52 | -91.0 ± 84.38 | -111.2 ± 125.57 |
| mg/dL | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| Week 16 | -29.4 ± 59.80 | -26.3 ± 50.89 |
| Week 24 | -68.8 ± 58.74 | -24.5 ± 90.23 |
| Week 36 | -47.6 ± 71.04 | 13.1 ± 129.20 |
| Week 52 | -55.1 ± 77.97 | 8.2 ± 75.10 |
| OLTP 5 Week 4 | -91.8 ± 61.29 | -39.8 ± 45.36 |
| OLTP 5 Week 12 | -82.9 ± 63.16 | -119.9 ± 64.64 |
| OLTP 5 Week 24 | -100.5 ± 55.15 | -40.7 ± 110.20 |
| OLTP 5 Week 52 | -91.0 ± 84.38 | -111.2 ± 125.57 |
| Percentage of change | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| Week 16 | -22.5 ± 48.21 | -50.2 ± 39.99 |
| Week 24 | -55.1 ± 30.60 | -45.7 ± 44.61 |
| Week 36 | -40.2 ± 39.19 | -43.9 ± 51.07 |
| Week 52 | -9.7 ± 74.05 | -60.3 ± 20.38 |
| OLTP 5 Week 4 | -71.5 ± 18.79 | -58.2 ± 21.60 |
| OLTP 5 Week 12 | -56.0 ± 38.07 | -80.0 ± 17.52 |
| OLTP 5 Week 24 | -64.4 ± 29.59 | -67.4 ± 22.32 |
| OLTP 5 Week 52 | -77.4 ± 13.37 | -85.8 ± 11.89 |
| Percentage of change | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| Week 16 | -39.4 ± 36.26 | -45.4 ± 47.97 |
| Week 24 | -62.8 ± 30.80 | -42.4 ± 53.75 |
| Week 36 | -48.6 ± 41.67 | -44.0 ± 60.31 |
| Week 52 | 0.7 ± 85.36 | -63.4 ± 22.22 |
| OLTP 5 Week 4 | -72.2 ± 20.92 | -58.2 ± 21.60 |
| OLTP 5 Week 12 | -54.9 ± 42.46 | -80.0 ± 17.52 |
| OLTP 5 Weeks 24 | -64.0 ± 33.06 | -67.4 ± 22.32 |
| OLTP 5 Week 52 | -77.4 ± 13.37 | -85.8 ± 11.89 |
| Percentage of HbA1c | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| Week 16 | -0.60 ± 2.200 | -0.50 ± 1.664 |
| Week 24 | -2.34 ± 1.897 | -0.85 ± 1.998 |
| Week 36 | -2.56 ± 1.985 | -0.83 ± 2.147 |
| Week 52 | -2.69 ± 2.120 | -1.59 ± 2.338 |
| OLTP 5 Week 12 | -3.57 ± 1.957 | -1.53 ± 2.472 |
| OLTP 5 Week 24 | -3.32 ± 2.294 | -1.45 ± 2.716 |
| OLTP 5 Week 52 | -1.67 ± 3.066 | -3.30 ± 2.821 |
| Percentage of HbA1c | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| Week 16 | -0.60 ± 2.200 | -0.36 ± 1.820 |
| Week 24 | -2.34 ± 1.897 | -0.77 ± 2.145 |
| Week 36 | -2.56 ± 1.985 | -0.74 ± 2.305 |
| Week 52 | -2.69 ± 2.120 | -1.65 ± 2.554 |
| OLTP 5 Week 12 | -3.57 ± 1.957 | -1.53 ± 2.472 |
| OLTP 5 Week 24 | -3.32 ± 2.294 | -1.45 ± 2.716 |
| OLTP 5 Week 52 | -1.67 ± 3.066 | -3.30 ± 2.821 |
| mg/dL | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| Week 16 | -10.626 ± 28.6416 | -7.579 ± 96.4257 |
| Week 24 | -73.634 ± 67.7436 | -49.107 ± 85.0349 |
| mg/dL | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| Week 16 | -10.626 ± 28.6416 | -4.510 ± 111.0606 |
| Week 24 | -73.634 ± 67.7436 | -53.797 ± 92.1541 |
| mg/dL*minutes | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| Week 8 | 829.3 ± 12465.83 | 1479.3 ± 6075.13 |
| Week 16 | -5300.7 ± 12605.15 | 3734.1 ± 22343.37 |
| Week 24 | -18000.6 ± 14760.99 | -5777.7 ± 14328.54 |
| mg/dL*minutes | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| Week 8 | 829.3 ± 12465.83 | 3098.2 ± 5145.73 |
| Week 16 | -5300.7 ± 12605.15 | 5976.4 ± 25141.92 |
| Week 24 | -18000.6 ± 14760.99 | -5828.2 ± 15695.44 |
| mg/kg/min | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| Week 8 | 0.030 ± 0.4224 | 4.789 ± 7.3736 |
| Week 52 | 6.256 ± NA | 4.776 ± 3.0924 |
| mg/kg/min | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| Week 8 | 0.030 ± 0.4224 | 0.572 ± 1.4186 |
| Week 52 | 6.256 ± NA | 3.740 ± 2.8121 |
| %mg/dL/min | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| Week 8 | 0.021 ± NA | 2.230 ± 2.4771 |
| Week 52 | 2.311 ± 0.1712 | 0.632 ± 0.2064 |
| %mg/dL/min | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| Week 8 | 0.021 ± NA | 2.230 ± 2.4771 |
| Week 52 | 2.311 ± 0.1712 | 0.632 ± 0.2064 |
| Participants | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| DBTP 1-3 | 7 | 8 |
| OLTP 4 | 8 | 7 |
| OLTP 5 | 1 | 6 |
| mg/L | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| Week 0 (post-dose) | 0 ± 0 | 49.2 ± 13.8 |
| Week 8 | 45.8 ± 6.82 | 2.51 ± 3.11 |
| Week 16 (post-dose) | 2.34 ± 3.44 | 50.6 ± 38.7 |
| Week 36 | 54.3 ± 36.4 | 67.7 ± 44.2 |
| Week 52 | 60.1 ± 45.1 | 68.8 ± 41.2 |
| OLTP 5 Week 4 | 167 ± 72.2 | 167 ± 60.6 |
| OLTP5 Week 12 | 185 ± 67.2 | 194 ± 80.6 |
| OLTP5 Week 36 | 156 ± 77.0 | 355 ± 166 |
| OLTP5 Week 52 | 196 ± 106 | 378 ± 224 |
| Participants | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| Number of Participants With Anti-drug Antibodies (ADA) to REGN4461 | 0 | 0 |
Absolute change from baseline in HbA1c for subgroup of participants with baseline HbA1c ≥7% reported
| millimoles per mole (mmol/mol) | Treatment Sequence A, DBTP 1: Placebo SC QW | Treatment Sequence B, DBTP 1: Low-dose REGN4461 SC QW |
|---|---|---|
| Absolute Change From Baseline in Participants With Elevated Baseline Hemoglobin A1c (HbA1c ≥7%) at Week 8 | -0.1 ± 0.6 | 0.2 ± 0.7 |
Absolute change from baseline in fasting glucose for subgroup of participants with baseline HbA1c ≥7% reported
| milligrams per deciliter (mg/dL) | Treatment Sequence A, DBTP 1: Placebo SC QW | Treatment Sequence B, DBTP 1: Low-dose REGN4461 SC QW |
|---|---|---|
| Absolute Change From Baseline in Fasting Glucose at Week 8 | 15.5 ± 18.6 | 53.6 ± 19.9 |
Absolute change from baseline in WMG for subgroup of participants with baseline HbA1c ≥7% reported
| mg/dL | Treatment Sequence A, DBTP 1: Placebo SC QW | Treatment Sequence B, DBTP 1: Low-dose REGN4461 SC QW |
|---|---|---|
| Absolute Change From Baseline in Weighted Mean Glucose (WMG) at Week 8 | -3.7 ± 19.9 | -3.7 ± 23.4 |
Percent change from baseline in participants with elevated baseline fasting TG (fasting TG ≥250 mg/dL) reported
| percentage of change | Treatment Sequence A, DBTP 1: Placebo SC QW | Treatment Sequence B, DBTP 1: Low-dose REGN4461 SC QW |
|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides (TG) at Week 8 | -6.0 ± 29.8 | 11.8 ± 29.8 |
Collected over From first dose of study drug through end of study (approximately 128 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Sequence A: DBTP 1 | 0/8 (0%) | 1/8 (12.5%) | 6/8 (75%) |
| Treatment Sequence B: DBTP 1 | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Treatment Sequence A: DBTP 2 | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| Treatment Sequence B: DBTP 2 | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Treatment Sequence A: DBTP 3 | 0/8 (0%) | 1/8 (12.5%) | 5/8 (62.5%) |
| Treatment Sequence B: DBTP 3 | 0/8 (0%) | 1/8 (12.5%) | 6/8 (75%) |
| Treatment Sequence A: OLTP 4 | 0/8 (0%) | 1/8 (12.5%) | 8/8 (100%) |
| Treatment Sequence B: OLTP 4 | 0/8 (0%) | 3/8 (37.5%) | 7/8 (87.5%) |
| Treatment Sequence A: OLTP 5 | 0/6 (0%) | 1/6 (16.7%) | 5/6 (83.3%) |
| Treatment Sequence B: OLTP 5 | 0/4 (0%) | 1/4 (25%) | 3/4 (75%) |
| Event | Treatment Sequence A: DBTP 1 | Treatment Sequence B: DBTP 1 | Treatment Sequence A: DBTP 2 | Treatment Sequence B: DBTP 2 | Treatment Sequence A: DBTP 3 | Treatment Sequence B: DBTP 3 | Treatment Sequence A: OLTP 4 | Treatment Sequence B: OLTP 4 | Treatment Sequence A: OLTP 5 | Treatment Sequence B: OLTP 5 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cardiac failureCardiac disorders | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/6 | 1/4 |
| COVID-19Infections and infestations | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 1/6 | 0/4 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 1/6 | 0/4 |
| Mesangioproliferative glomerulonephritisRenal and urinary disorders | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 1/6 | 0/4 |
| Pancreatitis necrotisingGastrointestinal disorders | 1/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/6 | 0/4 |
| Autoimmune thyroiditisEndocrine disorders | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 1/8 | 0/8 | 0/6 | 0/4 |
| Abdominal pain upperGastrointestinal disorders | 0/8 | 0/8 | 0/8 | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 | 0/6 | 0/4 |
| Stoma site infectionInfections and infestations | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 1/8 | 0/6 | 0/4 |
| Anastomotic ulcerInjury, poisoning and procedural complications | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 1/8 | 0/8 | 0/8 | 0/6 | 0/4 |
| Acute kidney injuryRenal and urinary disorders | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 1/8 | 0/6 | 0/4 |
| Event | Treatment Sequence A: DBTP 1 | Treatment Sequence B: DBTP 1 | Treatment Sequence A: DBTP 2 | Treatment Sequence B: DBTP 2 | Treatment Sequence A: DBTP 3 | Treatment Sequence B: DBTP 3 | Treatment Sequence A: OLTP 4 | Treatment Sequence B: OLTP 4 | Treatment Sequence A: OLTP 5 | Treatment Sequence B: OLTP 5 |
|---|---|---|---|---|---|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 0/8 | 2/8 | 0/8 | 3/8 | 1/8 | 1/8 | 3/8 | 4/8 | 0/6 | 1/4 |
| NauseaGastrointestinal disorders | 0/8 | 1/8 | 0/8 | 0/8 | 1/8 | 0/8 | 0/8 | 3/8 | 2/6 | 0/4 |
| VomitingGastrointestinal disorders | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 1/8 | 0/8 | 3/8 | 1/6 | 0/4 |
| Back painMusculoskeletal and connective tissue disorders | 1/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 1/8 | 2/6 | 1/4 |
| HypertensionVascular disorders | 0/8 | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 2/6 | 0/4 |
| COVID-19Infections and infestations | 1/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 2/8 | 1/8 | 0/6 | 0/4 |
| Urinary tract infectionInfections and infestations | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 2/8 | 0/6 | 0/4 |
| HypokalaemiaMetabolism and nutrition disorders | 1/8 | 2/8 | 0/8 | 0/8 | 0/8 | 0/8 | 1/8 | 2/8 | 0/6 | 0/4 |
| HeadacheNervous system disorders | 1/8 | 0/8 | 0/8 | 0/8 | 1/8 | 0/8 | 1/8 | 2/8 | 1/6 | 1/4 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/8 | 2/8 | 0/8 | 0/8 | 1/8 | 1/8 | 0/8 | 0/8 | 0/6 | 0/4 |
Double-blind safety analysis set (SAF) (all randomized participants who received any double-blind study drug. Participants analyzed according to the treatment received).
| Age, Continuous(Years) | Treatment Sequence A, DBTP 1-3 | Treatment Sequence B, DBTP 1 -3 | Total |
|---|---|---|---|
| Mean | 19.8 ± 4.95 | 30.3 ± 16.06 | 25.0 ± 12.70 |
| Sex: Female, Male(Participants) | Treatment Sequence A, DBTP 1-3 | Treatment Sequence B, DBTP 1 -3 | Total |
|---|---|---|---|
| Female | 6 | 8 | 14 |
| Male | 2 | 0 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Sequence A, DBTP 1-3 | Treatment Sequence B, DBTP 1 -3 | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 4 |
| Not Hispanic or Latino | 5 | 7 | 12 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment Sequence A, DBTP 1-3 | Treatment Sequence B, DBTP 1 -3 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 2 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 2 |
| White | 6 | 5 | 11 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All individual patient data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
Data sharing details ↗ · vivli.org
Ran from Jan 2020 to primary completion in Jan 2022, 23 months.
Results were first posted in Feb 2025, 3 years 1 month after primary completion. A results delay was requested in Jan 2023.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mibavademab
Lipodystrophy, Congenital Generalized